Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Saved in:
| Title: | Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. |
|---|---|
| Authors: | Levitt JE; Division of Pulmonary, Allergy, and Critical Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Hedlin H; Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Duong S; Stanford Center for Clinical Research, Stanford, CA, USA., Lu D; Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Lee J; Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Bunning B; Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Elkarra N; Stanford Center for Clinical Research, Stanford, CA, USA., Pinsky BA; Department of Pathology Stanford University School of Medicine, Stanford, CA, USA.; Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA., Heffernan E; Celltaxis LLC, Atlanta, GA, USA., Springman E; Celltaxis LLC, Atlanta, GA, USA., Moss RB; Pediatrics (Pulmonary Medicine), Center for Excellence in Pulmonary Biology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA., Bonilla HF; Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA., Parsonnet J; Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA., Zamanian RT; Division of Pulmonary, Allergy, and Critical Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Langguth JJ; Stanford Center for Clinical Research, Stanford, CA, USA., Bollyky J; Stanford Innovative Medicines Accelerator, Stanford, CA, USA., Khosla C; Stanford Innovative Medicines Accelerator, Stanford, CA, USA., Nicolls MR; Division of Pulmonary, Allergy, and Critical Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Desai M; Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Rogers AJ; Division of Pulmonary, Allergy, and Critical Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Jul 26; Vol. 77 (2), pp. 186-193. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
